Antonio Luciano
Overview
Explore the profile of Antonio Luciano including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
49
Citations
988
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Del Vecchio V, Mele L, Panda S, Sanchez-Pajares I, Mosca L, Tirino V, et al.
Cell Death Dis
. 2023 Sep;
14(9):613.
PMID: 37723219
The β2-Adrenergic receptor (β2-ARs) is a cell membrane-spanning G protein-coupled receptors (GPCRs) physiologically involved in stress-related response. In many cancers, the β2-ARs signaling drives the tumor development and transformation, also...
2.
De Luca V, Bozzetto L, Giglio C, Tramontano G, De Simone G, Luciano A, et al.
Front Public Health
. 2023 Sep;
11:1219661.
PMID: 37663860
Background: Self-management of Type 2 diabetes mellitus (T2D) is challenging. Regular self-monitoring of blood glucose and healthy lifestyles are required to improve glycometabolic control, thus delaying diabetes complications, and reducing...
3.
Conte C, Longobardi G, Barbieri A, Palma G, Luciano A, Dal Poggetto G, et al.
Int J Pharm
. 2023 May;
641:123045.
PMID: 37169105
No abstract available.
4.
Luca S, Franco R, Napolitano A, Soria V, Ronchi A, Marino F, et al.
Cancers (Basel)
. 2023 Apr;
15(7).
PMID: 37046851
Non-small cell lung cancer (NSCLC), the leading cause of cancer death worldwide, is still an unmet medical problem due to the lack of both effective therapies against advanced stages and...
5.
Tacconi E, Palma G, De Biase D, Luciano A, Barbieri M, de Nigris F, et al.
Nutrients
. 2023 Feb;
15(3).
PMID: 36771270
Trimethylamine N-oxide (TMAO) is a microbial metabolite derived from nutrients, such as choline, L-carnitine, ergothioneine and betaine. Recently, it has come under the spotlight for its close interactions with gut...
6.
Quagliariello V, Passariello M, Di Mauro A, Cipullo C, Paccone A, Barbieri A, et al.
Front Cardiovasc Med
. 2023 Feb;
10:1129873.
PMID: 36742077
[This corrects the article DOI: 10.3389/fcvm.2022.930797.].
7.
Conte C, Longobardi G, Barbieri A, Palma G, Luciano A, Dal Poggetto G, et al.
Int J Pharm
. 2023 Jan;
633:122618.
PMID: 36657553
Surface functionalization of nanoparticles (NPs) with tumor-targeting peptides is an emerging approach with a huge potential to translate in the clinic and ameliorate the efficacy of nano-oncologicals. One major challenge...
8.
Quagliariello V, Basilicata M, Pepe G, De Anseris R, Di Mauro A, Scognamiglio G, et al.
J Cardiovasc Dev Dis
. 2022 Dec;
9(12).
PMID: 36547420
Anthracyclines are essential adjuvant therapies for a variety of cancers, particularly breast, gastric and esophageal cancers. Whilst prolonging cancer-related survival, these agents can induce drug-related cardiotoxicity. Spirulina, Reishi (Ganoderma lucidum)...
9.
Quagliariello V, Passariello M, Di Mauro A, Cipullo C, Paccone A, Barbieri A, et al.
Front Cardiovasc Med
. 2022 Sep;
9:930797.
PMID: 36158826
Background: Immune checkpoint inhibitors (ICIs) have significantly changed the oncology clinic in recent years, improving survival expectations in cancer patients. ICI therapy have a broad spectrum of side effects from...
10.
Ierano C, Righelli D, DAlterio C, Napolitano M, Portella L, Rea G, et al.
J Immunother Cancer
. 2022 Mar;
10(3).
PMID: 35246475
Background: Colorectal cancer (CRC) is one of the most prevalent and deadly tumors worldwide. The majority of CRC is resistant to anti-programmed cell death-1 (PD-1)-based cancer immunotherapy, with approximately 15%...